AFM
CAPR icon

Anson Funds Management’s Capricor Therapeutics CAPR Stock Holding History

Anson Funds Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$602K Buy
+25,000
New +$758K 0.04% 153
2026
Q1 		– Sell
-68,018
Closed -$1.96M – 136
2025
Q4 		$1.96M Buy
+68,018
New +$888K 0.19% 75

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Anson Funds Management's CAPR Position: Q2 2026 in Review

Anson Funds Management opened a new position in Capricor Therapeutics (CAPR) in Q2 2026: 25,000 shares worth $602K. The stake represents 0.04% of the portfolio and ranks #153 among its holdings. This is a return to the name: Anson Funds Management previously reported a position in CAPR as recently as Q4 2025.

Anson Funds Management first reported a position in CAPR in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.96M in Q4 2025. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Anson Funds Management held 25,000 shares of Capricor Therapeutics worth $602K as of Q2 2026.
  • Capricor Therapeutics was a new Anson Funds Management position in Q2 2026.
  • Capricor Therapeutics made up 0.04% of Anson Funds Management's portfolio in Q2 2026, its #153 holding.
  • Anson Funds Management first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Anson Funds Management's Capricor Therapeutics position peaked at $1.96M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Anson Funds Management's 13F filing for Q2 2026, filed 13 Aug 2026.